Genetic Technologies Ltd. ADR (GENE) News
Filter GENE News Items
GENE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GENE News Highlights
- GENE's 30 day story count now stands at 2.
- Over the past 13 days, the trend for GENE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ASX are the most mentioned tickers in articles about GENE.
Latest GENE News From Around the Web
Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer SymposiumMELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Spaeth at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend. The Poster titled “Improvement of a clinical colorectal cancer risk prediction model integrating polyg |
Genetic Technologies Provides Business UpdateMELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to provide the following business update for the first half of the 2023 financial year. Operating in the multibillion dollar predictive and consumer genomics markets, GTG has achieved five consecutive quarters of growth. Our portfolio features the most comprehensi |
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetesMELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the geneType Multi-Risk Test. The paper is coauth |
Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious diseaseMELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical & Scientific Affairs and GTG in the US) and Adjunct Professor Charles Siles Health (Executive Director and founder of Siles Health). A/Prof. Charles Siles, Obstetrician and Gynaecologist operates nine (9) clinics across Vic |
Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer PreventionMELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Canc |
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar DetailsMELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23). Q1 FY23 Highlights: Revenue from customers of A$1.93 million for the quarter, up 375% from prior corresponding period (Q1 FY22), highlighting commercial progress with revenues anchoring from GTG’s |
Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Eastern Time (ET). |
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancerMELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician. Publication highlig |
Genetic Technologies Provides Update on US Operations and Payer EngagementMELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates: Strategic Highlights: Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of livesEngagement wi |
GENE Momentum building - a year in reviewMELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022. It has been an exciting 12 months focused on our commercialisation journey. We now have the most comprehensive portfolio of genetic based tests available for individuals and animals. In addition to our p |